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Positive margins dominate clinical outcomes after surgical resections in most solid cancer 
types including head and neck squamous cell carcinoma. Unfortunately, surgeons remove 
cancer in the same manner they have for a century with complete dependence on subjective 
tissue changes to identify cancer in the operating room. To effect change, we hypothesize 
that epidermal growth factor receptor (EGFR) can be targeted for safe and specific real-time 
localization of cancer. 
EXPERIMENTAL DESIGN
A dose escalation study of cetuximab conjugated to IRDye800 was performed in patients 
(n=12) undergoing surgical resection of squamous cell carcinoma arising in the head and 
neck.  Safety and pharmacokinetic data were obtained out to 30 days post-infusion. Multi-in-
strument fluorescence imaging was performed in the operating room and in surgical pathol-
ogy. 
RESULTS
There were no grade 2 or higher adverse events attributable to cetuximab-IRDye800. Fluo-
rescence imaging with an intraoperative, wide-field device successfully differentiated tumor 
from normal tissue during resection with an average tumor-to-background ratio of 5.2 in the 
highest dose range. Optical imaging identified opportunity for more precise identification of 
tumor during the surgical procedure and during the pathological analysis of tissues ex-vivo. 
Fluorescence levels positively correlated with EGFR levels.  
CONCLUSION
We demonstrate for the first time that commercially available antibodies can be fluorescently 
labeled and safely administered to humans to identify cancer with sub-millimeter resolution, 
which has the potential to improve outcomes in clinical oncology.
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INTRODUCTION
The primary treatment for many solid cancers remains surgical resection with negative mar-
gins which requires accurate identification of cancer in real-time. Patients with squamous 
cell carcinoma arising in the head and neck region often undergo surgical extirpation as part 
of their primary or salvage treatment.1 The incidence of involved or close surgical margins 
approaches 40% on histopathological review,2,3 resulting in a significantly worse outcome.4 
Positive margins rates have not significantly changed over the past several decades because 
surgeons cannot successfully differentiate normal and diseased tissue.
Failure to identify residual disease in this patient population is not surprising considering 
that the surgeon must rely on non-specific visual changes and manual palpation of subtle 
irregularities to guide successful excision. The most common method of intraoperative mar-
gin control remains frozen section analysis, however this technique is time intensive and can 
sample only a small fraction of the wound bed. To address the need for intraoperative cancer 
identification, conventional anatomical imaging modalities have been adopted for use in the 
operating room. Unfortunately, these are neither real-time nor tumor specific, and do not 
allow surgical field of view.  Cancer-specific navigation has been successfully introduced in 
glioma surgery with improvement in outcomes,5-7 but this strategy lacks specificity and ap-
plicability to other cancer types.8 Adapting therapeutic antibodies for intraoperative cancer 
imaging leverages the known safety profile of the antibody to facilitate the clinical translation 
of the technique for surgical navigation in oncology.9,10
Based on extensive preclinical data establishing the feasibility of antibody-based imaging,11,12 
we hypothesize that fluorescently labeled anti-epidermal growth factor receptor (EGFR) anti-
body would be safe and enable detection of squamous cell cancer in humans.13,14 Over 90% of 
head and neck tumors are known to overexpress EGFR.15-17 We selected IRDye800 for optical 
labeling for this study because previous rodent studies show a lack of toxicity,18 the dye is 
manufactured under conditions suitable for human use, and preclinical studies in non-hu-
man primates comparing cetuximab-IRDye800 to cetuximab alone showed no clinically sig-
nificant toxicities.19    
The safety and tumor specificity of optically labeled antibodies has not been previously as-
sessed in humans.  To this end, we evaluated escalating doses of cetuximab-IRDye800 in a 
phase I clinical trial to localize microscopic fragments of cancer during operative and patho-




Patients scheduled to undergo surgical extirpation were identified in the otolaryngology clin-
ic at the University of Alabama at Birmingham. Of the 14 individuals aged 40–84 years with 
biopsy proven squamous cell carcinoma of the head and neck that were evaluated for trial el-
igibility, 12 were enrolled.  Patients were not enrolled if they had an allergic reaction to either 
a 10mg or 100mg test dose of unlabeled cetuximab. Karnofsky score of greater than 70% and 
normal electrolyte parameters were required. All patients were given informed consent and 
the UAB Institutional Review Board approved the study.  The FDA approved the study proto-
col (NCT01987375) and the manufacturing process of the cetuximab-IRDye800 by the UAB 
Vector Production Facility as previously described.19 Because this was a first in human study 
with the conjugated antibody, it was unknown whether immunological reaction may limit 
dosing and optimal tumor to background ratio.  Sample size was based on traditional 3+3 
phase I dose escalation model to identify the optimal tumor to background ratio. Consented 
patients meeting study criteria were admitted to the infusion center for study drug adminis-
tration.  A pretreatment dose of 10mg or 100mg unlabeled cetuximab was administered prior 
to the study drug to differentiate between a cetuximab reaction and a cetuximab-IRDye800 
reaction.  During and after cetuximab-IRDye800 infusion, hemodynamic measurements and 
ECG data were obtained.  The escalating doses were based on the therapeutic dose of cetux-
imab (250mg/m2).  The first three patients (cohort 1) were given a microdose (1% of thera-
Figure 1. Trial Imaging Workflow.  Real-time imaging was performed with a wide-field near-infrared imaging system in 
the clinic on (1) Day 0, 1, and in the (2) operating room on day 3 post cetuximab-IRDye800 infusion. (3) During post-
resection processing, resected tissues were imaged with a closed-field near-infrared imaging system. (4) Following 
histologic preparation, a corresponding slide was imaged in surgical pathology using a fluorescence scanning system.  
Figure  Tri l I ging Workflow. Real-ti e imaging was p rformed with a wide-field near-infrared i ag-
ing system in the clinic on (1) Day 0, 1, and in the (2) operating room on day 3 post cetuximab-IRDye800 
infusion. (3) During post-resection processing, resected tissues were imaged with a closed-field near-in-
frared imaging system. (4) Following histologic preparation, a corresponding slide was imaged in surgical 




































































































































































































































































































































































































































































































































































































































































































































































peutic dose), cohort 2 received 10% of therapeutic dose, and cohort 3 received 25% therapeu-
tic dose (Table 1). No outliers were excluded from the study analysis.
CETUXIMAB-IRDYE800 CONJUGATION
Conjugation of cetuximab-IRDye800 was performed under cGMP conditions, as previously 
described.19 Briefly, cetuximab® (ImClone LLC, Eli Lilly and Company, Branchburg, NJ) was 
concentrated and pH adjusted by buffer exchange to a 10mg/ml solution in 50mM potassium 
phosphate, pH 8.5. IRDye800CW NHS ester (LI–COR Biosciences, Lincoln NE) was conju-
gated to cetuximab for 2hr at 20ºC in the dark, at a molar ratio of 2.3:1.   
OPTICAL IMAGING
Wide-field near-infrared (NIR) imaging: Routine imaging of the tumor, cervical skin, and fore-
arm skin was performed in the clinic on day 0 and 1 post cetuximab-IRDye800 infusion 
using a wide-field optical imaging device (Luna Imaging System, Novadaq, Toronto, Canada) 
designed for intraoperative imaging of indocyanine-green (ICG). For surgical imaging, the 
protocol stipulated that the imaging data would not be used to guide the surgical procedure. 
Routine intraoperative equipment was used.  The existing equipment could easily be wheeled 
into the OR and requires mere minutes to acquire fluorescence imaging. The tumor was im-
aged using the wide-field system prior to resection and ex vivo at post-resection. The wound 
bed was also imaged after removal of tumor and margins.  During wide-field acquisition, 
video (30s at 7.5f/s and 1/15s or 1/4s integration) of specimen in field of view (30cm or 15cm 
from camera) was collected at each time-point. Quantitative analysis was performed using 
integrated instrument software (SPY-Q, Novadaq). Relative fluorescent units (RFU) were 
measured for tumor and background (area surrounding tumor) and averaged among six in-
dividual frames per imaging time-point.  Tumor-to-background ratio (TBR) was calculated 
by dividing tumor RFU by respective background RFU as described previously.13 For quali-
tative analysis, exported DICOMs were used to produce videos and images in SPY-Q using 
standardized threshold values. 
Closed-field NIR imaging: The Pearl Impulse imaging platform (LI–COR Biosciences, Lincoln, 
NE) was used to image fresh tissues obtained in the operating room prior to paraffin embed-
ding. For cohort 1 (2.5mg/m2), there were three primary tumors resected from three patients 
yielding 42 bread-loafed specimens. Multiple wound-bed margins (n=27), muscle (n=6), and 
skin samples (n=6) were also collected and imaged.  In cohort 2 (25mg/m2), there were four 
primary tumors were imaged from three patients yielding 46 individual specimens.  Imaging 
was also performed on the wound-bed margins (n=26), muscle (n=6), and skin (n=6) sam-
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ples. In cohort 3 (62.5mg/m2), there were three primary tumors from three patients yielding 
22 individual specimens.  Imaging was also performed on the wound-bed margins (n=12), 
muscle (n=6), and skin (n=6) samples. Only one intraoperative frozen margin, produced in 
cohort 3 by patient 12, was histologically-confirmed positive for disease. Tissue thickness of 
fresh tissue samples was maintained at 4–5mm to normalize for attenuation. For quantitative 
analysis, mean fluorescent intensity (MFI), defined as total counts/region of interest (ROI) 
pixel area, was calculated using custom ROI generated for each specimen using integrated 
instrument software (ImageStudio, LI–COR Biosciences). 
HISTOLOGICAL ASSESSMENT
Routine H&E staining was done for histological assessment performed by a board-certified 
pathologist and then correlated with fluorescence intensity. The Odyssey imaging platform 
(LI–COR Biosciences) was used to determine fluorescence in slide-mounted sections ob-
tained from paraffin-embedded blocks. To quantify the fluorescence signal, ROIs were drawn 
in the tumor region (determined by pathologist) and compared with fluorescence of adjacent 
normal tissue and muscle from remote sites (collected during standard-of-care surgery). This 
was repeated in three tumor-containing areas of the same slide resulting in an average MFI for 
each specimen. Immunohistochemistry on unstained tissue sections of tumor, normal, and 
muscle was performed to evaluate EGFR expression (anti–EGFR Ab–10, Thermoscientific, 
Waltham, MA) and tumor density (anti-pan Cytokeratin Ab-961, Abcam, Cambridge, MA). 
Stained slides were imaged using the Bioimagene (Ventana Medical Systems, Tucson, AZ) 
optical scanner. 
ADVERSE EVENTS
Adverse events were classified according to the National Cancer Institute Common Terminol-
ogy Criteria (Version 4.0).  Plasma chemistry profiles (sodium, potassium, chloride, magne-
sium, calcium, BUN, creatinine, phosphorus, albumin, alkaline phosphatase, ALT, AST, total 
bilirubin, total protein) for analysis were obtained up to 14 days before surgery and at the 
following time points: day 0, day 3–4 (date of surgery) and as needed for adverse event assess-
ment. Complete blood count with differential and platelets were obtained at baseline along 
with coagulation lab values and thyroid stimulating hormone.  General physical exam and 
Karnofsky performance status were assessed prior to enrollment and at days 0, 1, 3–4 (date of 






























































































































< Figure 2 Quantification of wide-field fluorescence imaging. Relative fluorescent units (RFU) ac-
quired during wide-field fluorescent imaging of tumor, background and tumor-to-background ratio (TBR) 
are shown for (a) 2.5mg/m2 cohort, (b) 25mg/m2 cohort, and (c) 62.5mg/m2 cohort. White light and fluores-
cence images acquired using wide-field imaging device are shown for (d) 2.5mg/m2 cohort, (e) 25mg/m2 
cohort, and (f) 62.5mg/m2 cohort. Asterisk denotes significant (p<0.05) increase in tumor RFU compared 
to background for respective day. Data are RFU and TBR ± SD.2
STATISTICAL ANALYSIS
The biostatistician examined the data graphically and calculated descriptive statistics for vari-
ables of interest. Differences in fluorescence by tissue type (cancerous versus normal margins; 
and cancerous versus distal muscle) were tested separately for each dose. Because patients 
contributed multiple tissue samples and some measurements of cancerous and normal mar-
gin fluorescence were made on the same histologic slide, formal testing of differences was 
done with linear mixed models, incorporating patients and slides as random effects and ac-
counting for the nesting of slides within patients. Descriptive statistics and graphical summa-
ries were done using SAS, SPSS, Excel, and R v 3.0.1.  Mixed modeling was done using the 
lme4 package in R.
RESULTS
PATIENTS AND SAFETY DATA
There were 14 patients who met study criteria, of which two had an infusion reaction to an 
unlabeled cetuximab test dose prior to receiving cetuximab-IRDye800 and were not enrolled. 
There were 12 patients (Table 1) who received the study drug; three at the 2.5mg/m2 and 
62.5mg/m2 dose, and six at the 25mg/m2 dose. All patients had biopsy proven squamous cell 
carcinoma originating in the head and neck.  There were no grade-2 or higher adverse events 
attributable to cetuximab-IRDye800 and four possibly related grade-1 adverse reactions oc-
curred in the first cohort, seven in the second cohort, and two in the third cohort (Table 1). 
Most common adverse events included tumor-site symptoms (n=4) and cardiovascular-relat-
ed findings (n=4). Patient-specific adverse events are listed in Table 1. Although sample size 
was limited, at no time point did paired t-tests indicate that the mean QTc was significantly 
prolonged compared to baseline, either overall or within each cohort (smallest P = 0.10). 
Also, graphical examination of changes in QTc over time did not suggest a coherent pattern 
of prolongation. As shown in Supplementary Figure S1A, the total plasma concentration of 
cetuximab-IRDye800 for 25mg/m2 was significantly (P<0.05) greater than the 2.5mg/m2 total 
plasma concentration at each time point. Additionally, the total plasma concentration for 
the 62.5mg/m2 was significantly (P<0.05) greater than the 25mg/m2 total plasma concentra-
tion at each time point. For all doses, the calculated half-life for the study drug was: 25hr in 
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cohort 1, 24hr in cohort 2, and 32hr in cohort 3 (Supplementary Fig. S1A).  Fluorescent gel 
electrophoresis also confirmed that the antibody-dye bioconjugate remained intact in serum 
(Supplementary Fig. S1B).
CLINICAL AND OPERATIVE FLUORESCENCE IMAGING
Wide-field NIR imaging (Luna Imaging System, Novadaq, Toronto, Canada) was performed 
post-cetuximab-IRDye800 infusion on day 0, 1, and the day of surgical resection. As shown 
in Fig. 2A, limited fluorescent signal was detectable by wide-field imaging above background 
in the first cohort (microdose level, 2.5mg/m2). In patients receiving 25mg/m2 and 62.5mg/
m2, quantitative analysis of wide-field imaging revealed significantly (P<0.05) greater fluo-
rescence detected in the tumor compared to surrounding normal tissue at each imaging time 
point (Fig. 2B, C). TBR was also shown to improve from day 1 to surgery with an average TBR 
increase of 2.2 for cohort 3.  Representative images of white light and fluorescence are shown 
in Fig.2d–f for respective patients at each cohort on surgery day.  Fluorescence imaging of the 
primary tumor in situ demonstrated fluorescence with an average TBR of 4.3 (2.1 – 7.8) for 
cohort 2 and an average TBR of 5.2 (4.8 – 6) for cohort 3. 
FLUORESCENCE IMAGING OF PRIMARY TUMOR RESECTION
During the trial, intraoperative imaging of the primary tumor prior to resection was per-
formed using the wide-field device. As shown in Figure 3, grayscale (Fig. 3A, D) and color 
(Fig. 3B, E) fluorescence imaging provided robust contrast between tumor and surrounding 
tissues during near-total glossectomy (Fig. 3C) and wide local excision (Fig. 3F) procedures 
Figure 3. Intraoperative fluorescence imaging. Shown are (A,D) grayscale fluorescence, (B,E) color map fluorescence, 
and (C,F) corresponding brightfield acquired using the wide-field device prior to primary tumor resection from patients in the 
25mg/m2 dose group undergoing a total glossectomy (A-C) and a wide local excision of the buccal mucosa (D-F).  
E D F 
A B C 
Figur  traoperative fluorescence imaging. Shown are (A,D) g ayscale fluorescence, (B,E) color 
map fluorescence, and (C,F) corresponding brightfield acquired using the wide-field device prior to prima-
ry tumor resection from patients in the 25mg/m2 dose group undergoing a total glossectomy (A-C) and a 
wide local excision of the buccal mucosa (D-F). 
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from the 25mg/m2 dose group. Quantitative analysis revealed TBR values of 3.2 for Figure 
3A-B and 4.1 for Figure 3D-E. The intraoperative imaging performed in these cases is shown 
in Supplementary Video 1, 2.  
CORRELATION OF FLUORESCENCE WITH HISTOLOGICAL DISEASE
To evaluate relationship between fluorescence intensity and tumor deposition, wide-field flu-
orescence imaging and pathological processing of the primary specimen was mapped to his-
tology (Fig.4). Closed-field fluorescence imaging of freshly processed, whole tissue sections 
(4-5mm thick, mapped with roman numerals) was performed and fluorescence intensity was 
shown to correlate with disease areas as determined by board-certified pathologist using H&E 
stain (marked with black dotted line in adjacent histological sections). The tumor border is 



























Figure 4 Correlation of fluorescence and disease margin. Wide-field fluorescence (A) and brightfield 
(B) image are shown of resected primary tumor. Gridlines represent whole tissue (4-5mm) sections cut 
during pathological processing of specimen. Breadloaf sections were fluorescently imaged using closed-
field imaging device, then formalin-fixed, sectioned, and H&E stained. Black outline represents tumor 
deposition as determined by board-certified pathologist. Fluorescent images of whole tissue sections and 
corresponding H&E stained sections are oriented with mucosal side at top. 
84
TUMOR MAPPING EX VIVO
Tumor mapping of the surgical specimen was performed ex vivo with a closed-field NIR imag-
ing system, the Pearl Impulse (LI–COR Biosciences, Lincoln, NE). Localization of IRDye800 
fluorescence in freshly resected tissue prior to paraffin embedding was performed to deter-
mine the ability of tumor fluorescence to differentiate tumor from normal tissues and identi-
fication of positive margins. To achieve this we first performed a quantitative comparison of 
MFI from bread-loafed tissue specimens was performed (Fig. 5A) to validate the preferential 
uptake of IRDye800 fluorescence in cancer tissue.  Fluorescence in histologically confirmed 
tumor tissue was significantly greater (P<0.001) than negative epithelial margins, muscle, and 
skin for each dose. Using peripheral histologically confirmed negative margins to represent 
background, the calculated TBR for cohort 2 (9.5) was significantly (P<0.05) higher than the 
TBR for both cohort 1 (5.9) and cohort 3 (5.7). Representative white light and fluorescence 
images are also shown for tumor, margins, skin, and muscle for the 2.5mg/m2 (Fig. 5B–E), 
25mg/m2 (Fig. 5F–I), and 62.5mg/m2 (Fig. 5J-M) doses.  Although this first in human study 
was designed not to interfere with standard of clinical care, several observations indicated 
the clinical benefit of ex vivo tumor fluorescence tumor mapping.  In one case the tumor was 
under-resected and ex vivo fluorescence imaging of tumor margins identified a single deep 
























tumor margins skin muscle 
Figure 5. Fluorescent imaging of resected tissues. (a) Mean fluorescent intensity (MFI) are shown for freshly 
resected tumor, margin, skin, and muscle for the 2.5mg/m2, 25mg/m2, 62.5mg/m2 dose groups acquired using 
closed-field imaging system. Representative bright field and fluorescence images of tumor, margins, skin, and 
muscle are shown for the (b-e) 2.5mg/m2 dose group,  (f-i) 25mg/m2 dose group, and (j-m) 62.5mg/m2 dose 
group. Image scaling was kept consistent for representative images at each dose. Asterisk denotes significant 
(p<0.05) increase in tumor MFI compared to margins, skin, and muscle for respective dose. Scale bars 










































62.5mg/m2 25mg/m2 2.5mg/m2 
Dose 
Figure 5 Fluorescent imaging of resected tissues. (a) Mean fluorescent intensity (MFI) are shown for 
freshly resected tumor, margin, skin, and muscle for the 2.5mg/m2, 25mg/m2, 62.5mg/m2 dose groups ac-
quired using closed-field imaging system. Representative bri ht field and flu r scence images of tumor, 
margins, skin, and muscle are shown for the (b-e) 2.5mg/m2 dose group,  (f-i) 25mg/m2 dose group, and 
(j-m) 62.5mg/m2 dose group. Image scaling was kept consistent for representative images at each dose. 
Asterisk denotes significant (p<0.05) increase in tumor MFI compared to margins, skin, and muscle for 
respective dose. Scale bars represent 0.5cm or 0.25cm. Data are MFI ± SD. 
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positive for cancer during intraoperative frozen section assessment. The relative fluorescent 
counts of the positive margin were 2-fold higher (Supplementary Fig. S2B) than the nega-
tive margins (Supplementary Fig. S2C-E) when imaged using the wide-field, intraoperative 
instrument. In another patient the tumor was over resected; the surgeon committed to the 
resection margin (Supplementary Fig. S3A) prior to optical imaging.  Post-resection optical 
imaging (Supplementary Fig. S3B, brightfield) of a primary cutaneous squamous cell carci-
noma from cohort 1 (2.5mg/m2 dose) demonstrated that the surgical margin, as determined 
by pathological assessment, extended significantly (greater than 3 cm) beyond the optical 
margin, which was also predicted using closed-field (Supplementary Fig. S3C) and wide-field 
(Supplementary Fig. S3D) imaging. In this case, the surgical margins were overestimated by 
the surgeon based on non-specific changes associated with previous surgery and radiation 
in this patient.  Unfortunately, in the current study, inadequate number of positive margins 
prohibited statistical analysis. 
MOLECULAR CORRELATIONS
Because the IRDye800 survives pathological processing and can be localized with high reso-
lution in unstained paraffin sections, fluorescence intensity was correlated with the presence 
of histologically confirmed tumor, normal adjacent tissue, or muscle containing areas. In Fig. 
6A, a representative H&E stain is shown from the 25mg/m2 dose. Areas of tumor and nor-
mal tissue, as determined by board-certified pathologist, are annotated. Regions that were 
histologically positive for tumor were found to have significantly (P<0.001) higher fluores-
cence compared to normal tissue (Fig. 6B). Furthermore, univariate analysis within all doses 
showed a strong correlation (P<0.001) with EGFR expression (Fig. 6C) and tumor density 
(P<0.05).  In multivariate models, EGFR expression remained significantly associated with 
fluorescence intensity (P<0.001) but tumor density did not (P>0.05). MFI of pathology-pos-
itive tumor was significantly greater (P<0.001) than normal and muscle for each dose (Fig. 
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Figure 6 Histopathology and fluorescence localization. (a) Representative H&E image of tumor sec-
tions from the 25mg/m2 dose group. Pathology-positive areas of cancer are outlined: T=Tumor, N=Normal 
adjacent tissue. (b) Fluorescence image of fixed, unstained tumor section shown in panel (a) acquired 
using fluorescent scanner with inset magnified area of pathology-positive cancer and (c) EGFR stain. (d) 
Mean fluorescent intensity (MFI) acquired using fluorescent scanning of fixed unstained tissue sections is 
shown for tumor, normal adjacent, and muscle. Data are MFI ± SE. Asterisk denotes significant (p<0.001) 
increase in tumor MFI compared to normal and muscle for respective dose.
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DISCUSSION
Successful fluorescent labeling of commercially available antibodies for human use to localize 
disease with high resolution may represent a unique opportunity in oncologic imaging. We 
demonstrate for the first time that tumor overexpression of EGFR can be safely exploited for 
diagnostic imaging and this targeting approach produces tumor-to-background ratio suffi-
cient for surgical decision-making. Several important observations could be made based on 
this trial data, which will be highly relevant for the field. First, microdosing provides limited 
contrast and strategies that target tumor receptors should not be constrained to an explorato-
ry approach (Phase 0 trials). Second, tumor mapping ex vivo identified suspicious areas on 
the specimen and on peripheral margins to reduce sampling error. Third, adverse events of 
the labeled antibody were consistent with the known toxicity profile of unlabeled cetuximab. 
And finally, this optical labeling technique could be safely applied to other protein-based 
therapeutics to confirm successful targeting or assess off-target activity during early phase 
trials.
While the current study was a phase 1 safety trial and therefore did not alter the standard of 
care, the disease margin was correlated with the fluorescence margin generated from specific 
probe emission where feasible and examples of this process are provided. In figure 4, the 
pathological processing was registered with the whole specimen image and then correlated 
with the histopathological-determined disease margin, which is annotated in the adjacent 
H&E image. As shown in figure 6, this degree of correlation was also performed at the micro-
scopic level with representative H&E images of tumor sections from the 25mg/m2 dose group. 
Additionally, the supplementary intraoperative videos and figure 3 images demonstrate the 
level of real-time resolution afforded when using the fluorescence information compared to 
the adjacent brightfield images, which serve as current standard of care.
Systemic administration of cetuximab-IRDye800 had grade-1 toxicities in each cohort that 
occurred in a dose independent manner.  Fluorescent imaging using a wide-field, intraoper-
ative device could differentiate tumor from normal tissue with an average TBR of 5.2 in the 
higher dose range.  Over the 3–4 days post-infusion, a gradual increase in TBR was visible 
over time, suggesting that achieving peak TBR may require longer periods between infusion 
and surgical intervention, which is consistent with preclinical data.14,20 Tumor EGFR expres-
sion was strongly associated with fluorescence intensity and was an independent predictor 
of fluorescence when compared to tumor density. As a first in human trial, the protocol was 
designed not to alter the standard of care, however, in this limited study opportunities were 
identified to improve delivery of surgical ablation and pathological processing. 
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As a dose ranging study, the results support the middle dose of 25mg/m2. Evidence of receptor 
saturation at the highest dose was demonstrated among each imaging platform. For wide-
field imaging, which would guide intraoperative decision making, there was no significant 
difference in TBR between the 25mg/m2 and 62.5mg/m2 doses (4.3 to 5.2, respectively). For 
the closed-field system imaging, which was performed for fluorescence guided tumor map-
ping to validate tumor localization of IRDye800, the TBR was highest in the 25mg/m2 group 
(9.9) versus the 2.5mg/m2 group (5.9) and the 62.5mg/m2 group (5.7). When slide-mount-
ed sections were imaged for fluorescence, the TBR (determined using MFI values from pa-
thology positive tumor and adjacent normal areas) was highest for the 25mg/m2 group (2.9) 
compared to the 2.5mg/m2 (2) and 62.5mg/m2 groups (1.7). Due to the loss in optimal TBR 
associated with the highest dose, the 25mg/m2 cetuximab-IRDye800 dose was considered 
optimal among the nine patients evaluated.
Although this is the first in human use of fluorescently labeled antibodies for detection of 
microscopic disease, tumor-specific optical imaging has been applied in humans for surgical 
navigation of gliomas21,22 and ovarian cancer.23  The use of 5–ALA for glioma surgery has 
advanced to phase 3 clinical trials where it was shown to improve oncologic and function-
al outcomes.5 Although 5–ALA imaging has significant limitation for application outside of 
glioma surgery (dependent on a high tumor metabolic rates, possesses wavelengths with sub-
optimal tissue penetration), approval in Europe and subsequent studies have demonstrated 
that fluorescence-based surgical navigation can improve outcomes. The only other in human 
study was administration of folate-fluorescein agent, which was shown to identify metastatic 
peritoneal disease in three out of ten patients tested.24 Tumor detection was limited to patients 
with peritoneal metastasis with high folate receptor expression.
Labeling cetuximab with IRDye800 as an oncologic contrast agent has several unique advan-
tages including the ability to image multiple cancer types and develop other antibodies for 
optical imaging.  The known pharmacokinetics can be applied to manufacturing and trial 
design to achieve cost-effective and safe clinical translation.  Furthermore, use of an optical 
dye with excitation and emission wavelengths that overlap with ICG allows access to a large 
pool of existing intraoperative imaging devices for early-phase trials, which can reduce cost 
of widespread adoption of this technology.19 Clinical translation of novel probes has been 
limited because development of imaging agents is expensive, toxicities are unknown, and 
there is limited expected return compared to therapeutic agents.  Although the long half-life 
of antibodies may result in increased background several days following administration, the 
long circulating times may also increase cellular incorporation thereby achieving higher tu-
89
mor penetration over time compared to normal tissues.25,26 Despite the spectrum of targeting 
vectors proposed in preclinical studies, therapeutic antibodies applied to diagnostic purposes 
might provide the most straightforward path to the clinic.  
Here we demonstrate for the first time that antibodies can be fluorescently labeled for high res-
olution of identification of cancer for clinical application. We show that cetuximab-IRDye800 
can be safely administered as a tumor-specific contrast agent, which may be helpful for sur-
gical navigation to identify subclinical disease in EGFR-expressing tumors.  Fluorescently 
labeled therapeutic antibodies may also be valuable to measure tumor-specific uptake, phar-
macokinetics, and biodistribution in early phase clinical trials of these agents.  Furthermore, 
high-resolution localization of antibody-dye conjugates within tumor tissues (stroma, vas-
culature, and cancer cells) and within the cell using confocal microscopy may provide novel 
methodology for determining patients likely to respond to antibody-based therapeutics.  
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